Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC

被引：0

作者：

Waterhouse, D. M. ^{[1
]}

Rothschild, S. ^{[2
]}

Dooms, C. ^{[3
]}

Mennecier, B. ^{[4
]}

Bozorgmehr, F. ^{[5
]}

Majem, M. ^{[6
]}

van den Heuvel, M. ^{[7
]}

Linardou, H. ^{[8
,9
]}

Chul-Cho, B. ^{[10
]}

Roberts-Thomson, R. ^{[11
]}

Okamoto, I. ^{[12
]}

Blais, N. ^{[13
]}

Schvartsman, G. ^{[14
]}

Holmskov, K. ^{[15
]}

Chmielewska, I. ^{[16
]}

Forster, M. ^{[17
]}

Stollenwerk, B. ^{[18
]}

Obiozor, C. C. ^{[19
]}

Wang, Y. ^{[19
]}

Novello, S. ^{[20
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Univ Basel, Ctr Comprehens Canc, Med Oncol, Basel, Switzerland

[3] Univ Hosp, Dept Resp Dis, Leuven, Belgium

[4] Univ Hosp Strasbourg, Pulmonol Unit, Strasbourg, France

[5] Univ Hosp Heidelberg, Dept Thorac Oncol, Thoraxklin, Heidelberg, Germany

[6] Hosp Santa Creu & Sant Pau, Med Oncol, Serv Oncol Med, Barcelona, Spain

[7] Radboud Univ Nijmegen, Dept Resp Dis, Med Ctr, Nijmegen, Netherlands

[8] Metropolitan Hosp, Oncol Dept 4, Athens, Greece

[9] Metropolitan Hosp, Comprehens Clin Trials Ctr, Athens, Greece

[10] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr,Coll Med, Seoul, South Korea

[11] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA, Australia

[12] Kyushu Univ Hosp, Fukuoka, Japan

[13] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada

[14] Hosp Israelita Albert Einstein, Ctr Oncol & Hematol Einstein Famila Dayan Daycova, Sao Paulo, Brazil

[15] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[16] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland

[17] UCL, Canc Inst, London, England

[18] Amgen Europe GmbH, Rotkreuz, Switzerland

[19] Amgen Inc, Thousand Oaks, CA USA

[20] Univ Torino, Dept Oncol, San Luigi Hosp, Turin, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S37 / S38

页数：2

共 50 条

[41] Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
Dy, Grace K.
Govindan, Ramaswamy
Velcheti, Vamsidhar
Falchook, Gerald S.
Italiano, Antoine
Wolf, Juergen
Sacher, Adrian G.
Takahashi, Toshiaki
Ramalingam, Suresh S.
Dooms, Christophe
Kim, Dong-Wan
Addeo, Alfredo
Desai, Jayesh
Schuler, Martin
Tomasini, Pascale
Tran, Qui
Jones, Simon
Ang, Agnes
Anderson, Abraham
Hindoyan, Antreas A.
Hong, David S.
Li, Bob T.
CANCER RESEARCH, 2022, 82 (12)
[42] Data from CodeBreak 200 published in THE LANCET: Confirmed Superiority of Sotorasib over Docetaxel in Patients with non-small cell Lung Cancer with KRAS-G12C Mutation
不详
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (06)
[43] KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
Cappuzzo, Federico
Castro, Gilberto
Kang, Jin-Hyoung
Wu, Yi-Long
Brustugun, Odd Terje
Cheema, Parneet Kaur
Owonikoko, Taofeek K.
Longin, Anne-Sophie
Boran, Aislyn
Duan, Jiawei
Caparica, Rafael
Loong, Herbert H. F.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC
Cappuzzo, F.
Castro Junior, G.
Kang, J. H.
Wu, Y. L.
Brustugun, O. T.
Cheema, P. K.
Owonikoko, T. K.
Longin, A. S.
Duan, J.
Caparica, R.
Loong, H. H. F.
Chan, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E14 - E14
[45] Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Siena, S.
Yamaguchi, K.
Ruffinelli Rodriguez, J. C.
Corral de la Fuente, E.
Kuboki, Y.
Cremolini, C.
Victoria Ruiz, I.
Elez Fernandez, M. E.
Strickler, J. H.
Furqan, M.
Bashir, B.
Nduka, C.
Hippenmeyer, J.
Chan, E.
Xia, C.
Masuishi, T.
ANNALS OF ONCOLOGY, 2024, 35 : S429 - S430
[46] Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300)
Paez, D.
Meriggi, F.
Cremolini, C.
Folprecht, G.
Korantzis, I.
Chan, E.
Tran, Q.
Fakih, M. G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S734
[47] A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer.
Yaeger, Rona
Langer, Corey J.
Ruffinelli, Jose Carlos
Fakih, Marwan
Furqan, Muhammad
Machiels, Jean-Pascal H.
Saportas, Yaneth
Nolte-Hippenmeyer, Jane
Chan, Emily
Xia, Caihong
Masuishi, Toshiki
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 128 - 128
[48] A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C-mutated advanced pancreatic cancer
Mahalingam, Devalingam
Burns, Michael Charles
Kalyan, Aparna
Kircher, Sheetal Mehta
Kocherginsky, Masha
Mulcahy, Mary Frances
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
Skoulidis, Ferdinandos
Li, Bob T.
Govindan, Ramaswamy
Dy, Grace K.
Shapiro, Geoffrey
Bauml, Joshua
Schuler, Martin H.
Addeo, Alfredo
Kato, Terufumi
Besse, Benjamin
Anderson, Abraham
Ang, Agnes
Ngarmchamnanrith, Gataree
Tran, Qui
Velcheti, Vamsidhar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] Patient-reported outcomes from the phase III prostate HYPRO trial: urinary toxicity
Wortel, R. C.
Incrocci, L.
Pos, F. J.
Smeenk, R. J.
Krol, A. D. G.
Aluwini, S.
Witte, M. G.
Heijmen, B. J. M.
Heemsbergen, W. D.
RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S295 - S297

← 1 2 3 4 5 →